News | Cardiac Diagnostics | December 19, 2019

FDA Grants Breakthrough Designation to Ekos ECG-based Low Ejection Fraction Screening Algorithm

Technology designed to improve detection of heart failure, developed in collaboration with Mayo Clinic

Developed by Eko, a digital health company applying artificial intelligence (AI) in heart disease, the algorithm analyzes 15 seconds of ECG data collected from the Eko Duo digital stethoscope. The data can be collected during a physical exam and helps identify reduced left ventricular ejection fraction (LVEF), a measure commonly used to diagnose patients with heart failure.

December 19, 2019 — The U.S. Food and Drug Administration (FDA) has granted breakthrough status for a novel ECG-based algorithm that could provide an easily accessible screening test for heart failure. Developed by Eko, a digital health company applying artificial intelligence (AI) in heart disease, the algorithm analyzes 15 seconds of ECG data collected from the Eko Duo digital stethoscope. The data can be collected during a physical exam and helps identify reduced left ventricular ejection fraction (LVEF), a measure commonly used to diagnose patients with heart failure.

FDA Breakthrough Device designation helps accelerate the algorithm’s regulatory review and is only awarded to novel innovations that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases.

Heart failure affects about 5.7 million people in the U.S. alone and is most commonly detected by echocardiogram imaging tests that are not normally conducted during a physical exam. Because of limited access to echocardiography, heart failure is frequently diagnosed late, making life-prolonging treatment more challenging.

“The Breakthrough Device designation recognizes the vast unmet clinical needs in identifying heart failure early in patients, whether it be due to cost, inaccessibility, or misdiagnosis,” said Connor Landgraf, CEO and co-founder of Eko. “We look forward to working with the FDA to bring this algorithm to patients and to give clinicians a new tool to screen for low ejection fraction.”

“A low ejection fraction means that the heart pump is weak, which can lead to shortness of breath, swelling, exercise intolerance, or sudden death, so it is important to identify, as many treatments exist,” said Paul Friedman, M.D., chair of the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn. “This technology gives physicians a tool to detect heart disease earlier, and before it develops into a more serious illness. In effect, by imbedding the technology in a commonly used clinical tool – the stethoscope – all caregivers carry some of the diagnostic prowess of an expert cardiologist with them.”

Peer-Reviewed Data on Eko AI Algorithm Already Available

Eko’s low ejection fraction algorithm employs a deep neural network developed in collaboration with Mayo Clinic. The algorithm was first announced in a landmark publication in Nature Medicine in January 2019. In further clinical studies at Mayo Clinic, the DUO combined with the AI algorithm was able to detect ejection fraction < 35% with an area under the curve (AUC) of 0.90.

Mayo Clinic and Friedman have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

The FDA’s Breakthrough Device program helps patients gain more timely access to medical devices by expediting their development, assessment, and review, while preserving the statutory standard of reasonable assurance of safety and effectiveness for premarket approval and the statutory standards for granting a de novo request. This status does not mean the algorithm has received FDA clearance. 

Eko is building software, devices, and analysis algorithms for in-clinic heart disease screening, telemedicine, and monitoring patients at home. Its FDA cleared platform is used by thousands of clinicians treating tens of millions of patients around the world. The Eko DUO was named a 2019 Fast Company World Changing Ideas Finalist. 

For more information: ekohealth.com

Related Content

An example of DiA'a automated ejection fraction AI software on the GE vScan POCUS system at RSNA 2019.

An example of DiA'a automated ejection fraction AI software on the GE vScan POCUS system at RSNA 2019.

News | Artificial Intelligence | May 26, 2020
May 26, 2020 — DiA Imaging Analysis, a provider of AI based ultrasound analysis solutions, said it received a governm
A list of all the abnormalities the AI model classifies. This illustration only shows three representative leads (DII, V1 and V6).Fig. This is Figure 1 from the Nature Communications article.

A list of all the abnormalities the AI model classifies. This illustration only shows three representative leads (DII, V1 and V6).Fig. This is Figure 1 from the Nature Communications article.

News | Artificial Intelligence | May 19, 2020
May 19, 2020 — Artificial inte...
TeraRecon will accelerate innovation in its advanced visualization and AI platforms for image-related decision support to clinical specialists

TeraRecon's End-to-End AI Ecosystem

News | Artificial Intelligence | March 04, 2020
March 4, 2020 — SymphonyAI Group, an operating group of lea
The FDA granted marketing authorization of the Caption Guidance software to Caption Health Inc. in February 2020. It uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.

GE Healthcare partnered with the AI developer Dia to provide an artificial intelligence algorithm to auto contour and calculate cardiac ejection fraction (EF). The app is now available on the GE Vscan pocket, point-of-care ultrasound (POCUS) system, as seen here displayed at RSNA 2019. Watch a VIDEO demo from RSNA.

Feature | Artificial Intelligence | February 11, 2020 | Sanjay Parekh, Ph.D. 
February 7, 2020 – At the 2019 Radiological Society...
A new technology for detecting low glucose levels via electrocardiogram (ECG) using a non-invasive wearable sensor, which with the latest artificial intelligence (AI) can detect hypoglycemic events from raw ECG signals has been made by researchers from the University of Warwick.

A new technology for detecting low glucose levels via electrocardiogram (ECG) using a non-invasive wearable sensor, which with the latest artificial intelligence (AI) can detect hypoglycemic events from raw ECG signals has been made by researchers from the University of Warwick.

 

News | Artificial Intelligence | January 13, 2020
A new technology for detecting low glucose levels via electrocardiogram (ECG) using a non-invasive wearable sensor,...
Videos | Artificial Intelligence | November 07, 2019
Piotr Slomka explains how his team at Cedars-Sinai is working on intelligent patient risk prediction algorithms...
AI Could Use EKG Data to Measure Patient's Overall Health Status

Image courtesy of iStock

News | Artificial Intelligence | August 29, 2019
In the near future, doctors may be able to apply artificial intelligence (AI) to electrocardiogram data in order to...